How to buy Alzamend Neuro stock (Alzamend Neuro)

Alzamend Neuro is a biotechnology business based in the US. Alzamend Neuro shares (ALZN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.29 – an increase of 7.5% over the previous week. Alzamend Neuro employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Alzamend Neuro stock

Buy Alzamend Neuro stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Alzamend Neuro stock price (NASDAQ: ALZN)

Use our graph to track the performance of ALZN stocks over time.

Alzamend Neuro shares at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$1.29
52-week range	$1.06 - $12.90
50-day moving average more info button	$1.49
200-day moving average more info button	$4.49
Wall St. target price	$35.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-142.87

Is it a good time to buy Alzamend Neuro stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alzamend Neuro price performance over time

Historical closes compared with the close of $1.22 from 2024-12-16

1 week (2024-12-12)	2.52%
1 month (2024-11-19)	-12.86%
3 months (2024-09-19)	-30.29%
6 months (2024-06-18)	205.76%

1 year (2023-12-19)	27.08%
2 years (2022-12-19)	-99.02%
3 years (2021-12-17)	367.5
5 years (2019-12-15)	N/A

Alzamend Neuro financials

Gross profit TTM	$0
Return on assets TTM	-214.47%
Return on equity TTM	-4408.31%
Profit margin	0%
Book value	$-3.77
Market Capitalization more info button	$5.4 million

TTM: trailing 12 months

Alzamend Neuro share dividends

We're not expecting Alzamend Neuro to pay a dividend over the next 12 months.

You may also wish to consider:

Have Alzamend Neuro's shares ever split?

Alzamend Neuro's shares were split on a 1:10 basis on 15 July 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alzamend Neuro shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Alzamend Neuro shares which in turn could have impacted Alzamend Neuro's share price.

Alzamend Neuro share price volatility

Over the last 12 months, Alzamend Neuro's shares have ranged in value from as little as $1.06 up to $12.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alzamend Neuro's is -0.038. This would suggest that Alzamend Neuro's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Alzamend Neuro has bucked the trend.

To put Alzamend Neuro's beta into context you can compare it against those of similar companies.

• Sio Gene Therapies (SIOX.US): 1.085
• Voyager Therapeutics (VYGR.US): 0.889

Alzamend Neuro overview

Alzamend Neuro, Inc. , a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. .

Frequently asked questions

null
What percentage of Alzamend Neuro is owned by insiders or institutions?
Currently 4.553% of Alzamend Neuro shares are held by insiders and 0.941% by institutions. How many people work for Alzamend Neuro?
Latest data suggests 4 work at Alzamend Neuro. When does the fiscal year end for Alzamend Neuro?
Alzamend Neuro's fiscal year ends in April. Where is Alzamend Neuro based?
Alzamend Neuro's address is: 3480 Peachtree Road NE, Atlanta, GA, United States, 30326 What is Alzamend Neuro's ISIN number?
Alzamend Neuro's international securities identification number is: US02262M3088